Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Front-line Ph+ ALL (LAL1811)
NCT01641107Phase 2Completed
- Sponsor
- Incyte
- Start
- Dec 2014
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL), sponsored by Incyte. Primary endpoint: Complete Hematological Response at 6 months. Started Dec 2014; status: completed.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01641107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641107.